


PHARMACEUTICAL 2019

Equillium Inc. Rank 68 of 371





PHARMACEUTICAL 2019



Equillium Inc. Rank 68 of 371

The relative strengths and weaknesses of Equillium Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Equillium Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 376% points. The greatest weakness of Equillium Inc. is the variable Other Net Income, reducing the Economic Capital Ratio by 52% points.

The company's Economic Capital Ratio, given in the ranking table, is 51%, being 382% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	67,099
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,028
Liabilities, Non-Current	200
Other Assets	0
Other Compr. Net Income	5.3
Other Expenses	0
Other Liabilities	0
Other Net Income	-4,635
Property and Equipment	64
Research and Development	4,943
Revenues	0
Selling, General and Administrative Expense	3,672

Output Variable	Value in 1000 USD
Assets	67,163
Liabilities	2,228
Expenses	8,616
Stockholders Equity	64,935
Net Income	-13,250
Comprehensive Net Income	-13,248
Economic Capital Ratio	51%